Elmar  Schnee net worth and biography

Elmar Schnee Biography and Net Worth

Elmar J. Schnee serves as Independent Director of the Company. Mr. Schnee has served as a member of our board of directors since August 2014 and previously served as a director of Gentium (now a subsidiary of Jazz Pharmaceuticals plc) from May 2012 until April 2014. Mr. Schnee has served as Chief Operating Officer of MindMaze SA, a neuro-technology company, since June 2016. From November 2013 to August 2015, Mr. Schnee served as a non-executive director of Cardiorentis Ltd., a biopharmaceutical company, where he served as Chairman and Chief Executive Officer from October 2011 until November 2013. From 2003 to 2011, Mr. Schnee held various positions at Merck KGaA, a global pharmaceutical and chemical group. He joined Merck KGaA in 2003 as Managing Director of Merck Santé S.A.S. In January 2004, Mr. Schnee assumed responsibility for global operations of the ethical pharmaceuticals division of Merck KGaA, and in November 2005, Mr. Schnee was appointed as Deputy Member of the Executive Board responsible for the pharmaceuticals business. In 2006, he was appointed as a member of the Executive Board and General Partner of Merck KGaA, with responsibility for global pharmaceutical activities, and served in this position until 2011. Prior to Merck KGaA, Mr. Schnee held senior positions in strategy, business development and marketing at UCB SA, Sanofi-Synthélabo SA, Migliara/Kaplan Associates, Inc. and Fisons Pharmaceuticals PLC. In addition, Mr. Schnee currently serves on the boards of directors of two pharmaceutical companies, Stallergenes-Greer and Santhera Pharmaceuticals Holding AG, and four privately-held life sciences companies. Mr. Schnee holds both a bachelor’s degree in marketing and a master’s degree in marketing and general management from the Swiss Institute of Business Administration in Zurich. With his experience as Chairman and Chief Executive Officer of Cardiorentis Ltd., his operational experience at Merck KGaA and other companies.

How do I contact Elmar Schnee?

The corporate mailing address for Mr. Schnee and other Jazz Pharmaceuticals executives is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. Jazz Pharmaceuticals can also be reached via phone at (531) 634-7800 and via email at [email protected]. Learn More on Elmar Schnee's contact information.

Has Elmar Schnee been buying or selling shares of Jazz Pharmaceuticals?

Elmar Schnee has not been actively trading shares of Jazz Pharmaceuticals in the last ninety days. Most recently, Elmar Schnee sold 1,632 shares of the business's stock in a transaction on Thursday, August 5th. The shares were sold at an average price of $154.00, for a transaction totalling $251,328.00. Learn More on Elmar Schnee's trading history.

Who are Jazz Pharmaceuticals' active insiders?

Jazz Pharmaceuticals' insider roster includes Paul Berns (Director), Patricia Carr (SVP), Jennifer Cook (Director), Bruce Cozadd (Co-Founder, Chairman & CEO), Patrick Enright (Director), Renée Galá (CFO), Peter Gray (Director), Mary Henderson (SVP, Technical Operations), Robert Iannone (EVP), Philip Johnson (CFO), Finbar Larkin (SVP), Seamus Mulligan (Director), Kenneth O'Keefe (Director), Anne Oriordan (Director), Neena Patil (Insider), Samantha Pearce (SVP), Kim Sablich (EVP), Elmar Schnee (Director), Mark Smith (Director), Christopher Tovey (COO), and Rick Winningham (Director). Learn More on Jazz Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Jazz Pharmaceuticals?

During the last year, Jazz Pharmaceuticals insiders bought shares 1 times. They purchased a total of 12,000 shares worth more than $1,435,800.00. During the last year, insiders at the specialty pharmaceutical company sold shares 8 times. They sold a total of 15,262 shares worth more than $1,766,604.30. The most recent insider tranaction occured on December, 2nd when CEO Bruce C Cozadd sold 2,000 shares worth more than $242,340.00. Insiders at Jazz Pharmaceuticals own 4.2% of the company. Learn More about insider trades at Jazz Pharmaceuticals.

Information on this page was last updated on 12/2/2024.

Elmar Schnee Insider Trading History at Jazz Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/5/2021Sell1,632$154.00$251,328.00View SEC Filing Icon  
See Full Table

Elmar Schnee Buying and Selling Activity at Jazz Pharmaceuticals

This chart shows Elmar Schnee's buying and selling at Jazz Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Jazz Pharmaceuticals Company Overview

Jazz Pharmaceuticals logo
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.
Read More

Today's Range

Now: $123.73
Low: $121.19
High: $124.61

50 Day Range

MA: $119.15
Low: $108.05
High: $127.74

2 Week Range

Now: $123.73
Low: $99.06
High: $134.17

Volume

187,949 shs

Average Volume

672,842 shs

Market Capitalization

$7.48 billion

P/E Ratio

17.43

Dividend Yield

N/A

Beta

0.57